Abstract 526P
Background
Tracheal, Bronchus, and Lung (TBL) cancer is the 1st leading cause of deaths across Southeast Asia (SEA), East Asia (EA), and Oceania (OC). However, there has been a lack of estimates regarding the burden of TBL cancer across these regions in previous studies.
Methods
Utilizing the Global Burden of Disease Methodology, TBL cancer prevalence, incidence, mortality, and disabiity adjusted life years (DALYs) were analyzed by age, sex, year, across SEA, EA, and OC spanning from 1990-2019. We employed a regression framework to forecast TBL cancer deaths through 2040.
Results
The total prevalence of TBL cancer cases surged by 3.5 times, escalating from 344,251 (95% uncertainty interval: 301,687-388,590) in 1990 to 1,306,745 (1,116,313-1,513,254) in 2019. While deaths rose from 319,128 (282,904-359,206) to 914,442 (791,095-1,049,894) from 1990-2019. In terms of the age-standardized incidence rate (ASIR), there was an increase from 27.81 (24.65-31.15) to 37.13 (32.08-42.53) per 100,000 person years from 1990-2019. The highest annual percentage of change (APC) was witnessed in deaths, rising by 187%, and in DALYs, increasing by 143% from 1990-2019. Notably, China experienced the highest APC in ASIR (38%), followed by Indonesia (35%), and Taiwan (28%) from 1990-2019. Meanwhile, Indonesia exhibited the highest increase in age-standardized mortality rate (ASMR) at 36%, while the Maldives demonstrated the most notable decrease of 33% from 1990-2019. In 2019, individuals aged 65-69 accounted for the highest incidence (172,031), while those aged 70-74 saw the highest mortality (155,538). Moreover, male individuals consistently bore a greater burden than females over the past three decades. Projection indicates that the total number of deaths may reach 1,080,050 (705,751-1,800,670) by 2040.
Conclusions
TBL cancer constituted 26.21% of all deaths within the realm of cancer-related fatalities in SEA, EA, and OC in 2019. This study uncovers a consistent pattern of escalating burden, emphasizing a notable rise in fatalities and its implications for public health, necessitates comprehensive strategies that encompass both individual risk factors and systemic challenges.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract